ReviewFrontiers in molecular biosciences2026
Breast milk miRNAs and their potential role in the development of atopy in infants.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human breast milk is a dynamic biological fluid enriched with bioactive components, including extracellular vesicle-derived microRNAs (miRNAs), which have emerged as potential mediators of early immune programming. Growing evidence suggests that maternal atopic status can alter the breast milk miRNA profile, potentially shaping the infant's susceptibility to atopic disorders, such as atopic dermatitis, asthma, and food allergy. This review presents current research examining the link between breast milk miRNA composition and the development of atopy in infants, with a particular focus on maternal atopic status. Four studies met eligibility criteria and collectively demonstrate that maternal conditions such as asthma or atopic dermatitis are associated with distinct breast milk miRNA signatures. Certain miRNAs, e.g., miR-375-3p and miR-1290, show altered expression in the milk of atopic mothers. Elevated levels of miR-375-3p are associated with a reduced risk of infant atopic manifestations during the first year of life, including atopic dermatitis, food allergy, and wheezing. Conversely, miR-1290 is significantly upregulated in the milk of mothers with asthma and atopy during pregnancy, even after adjusting for confounders, highlighting its potential role as a biomarker of maternal allergic status. However, current findings rely primarily on statistical associations; no human study has yet demonstrated direct transfer or functional activity of milk-derived miRNAs in infants. Overall, while breast milk miRNAs represent a promising link between maternal health and infant atopy risk, conclusive evidence is lacking. Future large-scale, standardized, longitudinal studies integrating functional validation are needed to clarify mechanistic pathways and evaluate the potential of milk miRNAs as biomarkers or targets for early atopy prevention. Understanding the functional impact of breast milk miRNAs could facilitate the development of non-invasive biomarkers for predicting atopy risk, as well as early-life preventive strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.